-
Investing in biodefense companies, II
Billions of dollars are being spent on finding vaccines and treatments for possible bioterror attacks; investment analyst says that these billions of dollars in government spending notwithstanding, when considering an investment in a company doing R&D in the bioterror field, you should consider its non-terror-related biotechnology efforts, and the quality of its management team
-
-
Good results in tests for BioNeutral's anti-anthrax technology
New Jersey company uses its Ygiene formulation to kill anthrax spores on contact; formulation killed all anthrax spores exposed to the formulation in as little fifteen seconds
-
-
Universal biosensor would detect disease, bioterror attack, pollution
A consortium of U.K. research institutions, in collaboration with a Chinese University, work on developing a universal biosensor which would help in many types of detection — from home diagnosis of disease to chemical plant monitoring, anti-bioterrorism, and pandemic outbreak
-
-
Tom Daschle calls for greater U.S.-U.K. bioterror cooperation
Daschle: “The threat of bioterrorism will increase exponentially because biological agents used to carry out such attacks will continue to become more accessible and more technologically advanced”
-
-
Investing in biodefense companies
Billions of dollars are pouring into biodefense vaccines and treatments; do companies engaged in developing such vaccines and treatment offer attractive investment opportunities? The answer is a qualified “Yes” to this specific question — but a more resounding “Yes” when these companies’ other research and development endeavors are taken into consideration
-
-
India to test anthrax vaccine
India is worried about bioterror attacks by Islamic extremists; it starts testing the potency of U.S.-manufactured vaccine; initially enough doses will be stored to protect military personnel
-
-
OSHA issues guidance regarding storage of face masks, respirators
OSHA requests comments on proposed guidance on workplace stockpiling of respirators and face masks for pandemic influenza
-
-
Nanotechnology-based biosensor
NASA develops nanotechnology-based biosensor that can detect trace amounts of specific bacteria, viruses, and parasites; New York-based Early Warning, Inc. will initially market the sensor to water treatment facilities, food and beverage companies, industrial plants, hospitals, and airlines
-
-
Boston biolab: Panel urges review of possible lab threats
As community opposition to the almost-complete Boston University biolab continues, a panel of experts says neighborhood’s concerns — and safety — should not be excluded from consideration of final approval for lab opening
-
-
CDC biolab not ready after 2 1/2 years
A new CDC biosafety lab was supposed to open in the fall of 2005; it is still not open, and legislators begin to wonder why; they note that at the University of Texas Medical Branch in Galveston, it took less than seven months for its BSL-4 lab to become operational after construction was finished
-
-
Is the threat of bioterrorism exaggerated?
William Clark, professor and chair emeritus of immunology at UCLA, says it is
-
-
A dead end for free trade? I
Tightening border security along the U.S.-Canada border is hampering trade, experts say; delays owing to security checks have cascading effects, as supplies and raw materials are late arriving at manufacturing plants
-
-
Market for molecular diagnostic technologies to grow
The last few years have seen major strides forward in molecular diagnostic technologies; new report asses size of markets and opportunities in it
-
-
Detailed studies of U.S. disaster preparedness offer recommendations
Critical care panel tackles disaster preparation, surge capacity, and health care rationing; some recommendations require largely greater budgets; other pose profound ethical and moral questions
-
-
Past patients to provide fast flu vaccine to new patients
Currently it takes at least six months to produce a flu vaccine after a new strain appears; researchers find that a faster way would be to treat people with antibodies produced by earlier patients
-
The long view
Are We Ready for a ‘DeepSeek for Bioweapons’?
Anthropic’s Claude 4 is a warning sign: AI that can help build bioweapons is coming, and could be widely available soon. Steven Adler writes that we need to be prepared for the consequences: “like a freely downloadable ‘DeepSeek for bioweapons,’ available across the internet, loadable to the computer of any amateur scientist who wishes to cause mass harm. With Anthropic’s Claude Opus 4 having finally triggered this level of safety risk, the clock is now ticking.”
“Tulsi Gabbard as US Intelligence Chief Would Undermine Efforts Against the Spread of Chemical and Biological Weapons”: Expert
The Senate, along party lines, last week confirmed Tulsi Gabbard as Director of National intelligence. One expert on biological and chemical weapons says that Gabbard’s “longstanding history of parroting Russian propaganda talking points, unfounded claims about Syria’s use of chemical weapons, and conspiracy theories all in efforts to undermine the quality of the community she now leads” make her confirmation a “national security malpractice.”